A68 COST EFFECTIVENESS OF TIGHT CONTROL FOR CROHN’S DISEASE WITH ADALIMUMAB-BASED TREATMENT: ECONOMIC EVALUATION OF CALM TRIAL FROM CANADIAN PERSPECTIVE

BACKGROUND: Tight control (TC) for Crohn’s disease (CD), using symptoms plus biomarkers (faecal calprotectin, C-reactive protein) to direct adalimumab (ADA) treatment, was associated with improved outcomes and considered cost effective (from United Kingdom setting) compared to clinical management (C...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Can Assoc Gastroenterol
Autors principals: Panaccione, R, Colombel, J, Bossuyt, P, Baert, F, Vanasek, T, Danalioglu, A, Novacek, G, Armuzzi, A, Reinisch, W, Johnson, S, Buessing, M, Neimark, E, Petersson, J, Robinson, A M, Thakkar, R B, Lee, W, Skup, M, D’Haens, G
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Posters Of Distinction
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512606/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz006.067
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars